BACKGROUND: High-sensitivity cardiac troponin assays have better analytical precision and sensitivity than earlier-generation assays when measuring cardiac troponin at low concentrations. We evaluated whether use of a high-sensitivity assay could further improve risk stratification compared with a standard cardiac troponin assay.
RESULTS:
Of the 1159 patients, 76 died and 42 developed an acute myocardial infarction (AMI). Prognostic accuracy of hs-cTnT for death was significantly higher [area under ROC curve (AUC) 0.79, 95% CI 0.74 -0.84] than that of cTnT (AUC 0.69, 95% CI 0.62-0.76; P Ͻ 0.001). After adjustment for Thrombolysis in Myocardial Infarction (TIMI) risk score (that included the cTnT assay result), hs-cTnT above the 99th percentile (0.014 g/L) was associated with a hazard ratio for death of 2.60 (95% CI 1.42-4.74). Addition of hs-cTnT to the risk score improved the reclassification of patients (net reclassification improvement 0.91; 95% CI 0.67-1.14; P Ͻ 0.001). Subgroup analyses showed that this effect resulted from the better classification of patients without AMI at time of testing. hs-cTnT outperformed cTnT in the prediction of AMI during follow-up (P ϭ 0.02), but was not independently predictive for this endpoint.
CONCLUSIONS:
Concentrations of hs-cTnT Ͼ0.014 g/L improve the prediction of death but not subsequent AMI in unselected patients presenting with acute chest pain.
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Cardiac troponin is the preferred marker for diagnosing myocardial injury, owing to its myocardial tissue specificity and related sensitivity and its established utility for therapeutic decision making and risk stratification (1) (2) (3) . Several studies have demonstrated a strong and independent association of even small increases in cardiac troponin with an incremental risk for death or myocardial infarction (AMI) 7 (2, 4 -7 ) . Recently, the precision at low concentrations of cardiac troponin has been enhanced by improving available assays and developing newer high-sensitivity assays (8 -10 ) . The higher sensitivity of these assays has allowed for improved identification of patients with AMI presenting in the first 3 h following symptom onset (11, 12 ) . Recent analyses focusing on increases in cardiac troponin detected by the high-sensitivity assays but undetectable by prior-generation assays have demonstrated that even small increases are associated with a higher risk of death and other adverse outcomes (13) (14) (15) (16) (17) (18) . It is currently unknown, however, whether the prognostic information provided by high-sensitivity assays exceeds that provided by the previous cardiac troponin assays, or if decreased specificity diminishes the advantage of their higher sensitivity. A recent analysis suggested that one high-sensitivity cardiac troponin I assay was less predictive for the combined endpoint of death and AMI compared with an older, less sensitive cardiac troponin assay (19 ) .
Therefore, we examined whether the use of a highsensitivity cardiac troponin T (hs-cTnT) assay can improve risk stratification compared with a standard (fourth-generation) cardiac troponin assay (cTnT) in an unselected cohort of patients presenting to the emergency department with symptoms suggestive of AMI.
Methods

STUDY DESIGN AND POPULATION
The Advantageous Predictors of Acute Coronary Syndrome Evaluation (APACE) trial is an ongoing prospective, multicenter study designed and coordinated by the University Hospital Basel, Switzerland. Patients Ͼ17 years old presenting to the emergency department with symptoms suggestive of cardiac ischemia at rest or minor exertion within the last 12 h were enrolled after giving written informed consent. Patients with cardiogenic shock, terminal kidney failure requiring dialysis, or anemia requiring transfusion were excluded. Results of the diagnostic value of cardiac troponin in this cohort have been published (12 ) . The study was carried out according to the principles of the Declaration of Helsinki and approved by local ethics committees.
CLINICAL AND LABORATORY PROCEDURES
All patients underwent an initial clinical assessment including clinical history, physical examination, 12-lead electrocardiogram (ECG), continuous ECG monitoring, pulse oximetry, and standard blood tests. Evaluation and treatment of patients were left to the discretion of the attending physicians and were performed according to standard practice of the hospital and current guidelines. Cardiac troponin, creatine kinase, and myoglobin were measured at presentation and after 6 h as clinically indicated. The following cardiac troponin assays were used at the different study sites: Abbott Axsym ADV troponin I (cutoff for diagnosis of MI at the CV Ͻ10%: 0.16 g/L), Beckmann Coulter Accu troponin I (cutoff at CV Ͻ10%: 0.06 g/L), and Roche cTnT (fourth generation; cutoff at CV Ͻ10%: 0.035 g/L).
Blood samples for determination of standard cTnT and hs-cTnT were collected into serum tubes at time of presentation to the emergency department. Within 1 h, samples were frozen at Ϫ80°C until assayed in a blinded fashion in a dedicated core laboratory. We measured standard fourth-generation cTnT using a 1-step enzyme immunoassay based on electrochemiluminescence technology (Roche Diagnostics) with a limit of detection of 0.01 g/L, a 99th percentile cutoff point from a healthy reference population of Յ0.01 g/L, and a CV of Ͻ10% at 0.035 g/L.We measured hs-cTnT with a precommercial sandwich enzyme electrochemiluminescence immunoassay (Roche Diagnostics) that had a limit of detection of 0.005 g/L, a 99th percentile cutoff point of 0.014 g/L, and a CV of Ͻ10% at 0.013 g/L (20 ) . The assay was linear up to 10.0 g/L. Total imprecision ranged from 4.6% at 0.0034 g/L to 36.8% at 0.0103 g/L (21 ).
ADJUDICATED FINAL DIAGNOSIS AND FOLLOW-UP
The study procedure to determine the final diagnosis has been described (12 ) . Further details can be found in the Supplemental Data, which accompanies the online version of this article at http://www.clinchem.org/ content/vol57/issue9. After hospital discharge, patients were followed for up to 24 months. All data were adjudicated by 2 independent physicians. The endpoints for the present analyses were death from any cause and AMI (see online Supplemental Data for details). Because blood samples were drawn before the diagnosis of AMI, we also analyzed a combined endpoint of AMI as index event and AMI following index event within 2 years.
STATISTICAL ANALYSIS
To assess the sensitivity and specificity of different biomarkers and to compare their ability to predict death, AMI, and cardiovascular death or AMI during followup, we constructed ROC curves. We used the method described by DeLong for comparison of the area under the curve (AUC) of different ROC curves (22 ) . Cutoffs for both cTnT assays represented the 99th percentile of a healthy reference population (0.014 g/L for hscTnT). Because the 99th percentile of cTnT is unknown (below the lower limit of detection), the lower limit of detection was used as cutoff (0.010 g/L).
We compared Kaplan-Meier survival curves with log-rank tests and used Cox proportional hazards models to calculate hazard ratios (HRs) with associated 95% CIs. We tested several variables that can be associated with altered troponin concentrations, such as AMI, age, body mass index (BMI), and glomerular filtration rate (GFR) (10 ), for interaction with hs-cTnT in Cox models for death or AMI. If a significant interaction was found (P Ͻ 0.10), a subgroup analysis was included.
For multivariable adjustment and to test for an incremental value of hs-cTnT compared to cTnT, we used the Thrombolysis in Myocardial Infarction (TIMI) risk score for unstable angina/non-STelevation myocardial infarction (23 ) . In this wellvalidated clinical score, age Ն65 years, Ն3 cardiovascular risk factors, known significant coronary stenosis, ST-segment deviation, severe anginal symptoms in the last 24 h, use of aspirin in the last 7 days, and increased serum cardiac markers (centrally measured cTnT above cutoff in the present analysis) add 1 point each (score 0 -7 points). To evaluate the improvement gained in our multivariable model by adding hs-cTnT, we calculated the net reclassification improvement (NRI) and the integrated discrimination improvement (IDI) using algorithms developed by Frank Harrell (based on the method of Pencina et al. (24 ) , run in R, version 2.10.1, R Development Core Team). For all other statistical analyses, we used the PASW software package, version 18 (IBM SPSS). Unless stated otherwise, continuous gaussian variables were reported as mean (SD) and compared by 1-way ANOVA. Nongaussian variables identified by Kolmogorov-Smirnov test were described as median (interquartile range) and tested by the Mann-Whitney U test for 2 groups or the Kruskal-Wallis H test for Ͼ2 groups. We report discrete variables as counts (percentages) and tested differences between groups with the 2 or Fisher exact test when expected cell sizes were Ͻ5. In the 2-sided test, a P value Ͻ0.05 was regarded as significant.
Results
STUDY POPULATION
From April 2006 to June 2009, 1247 consecutive patients were enrolled for the present analysis. Measured concentrations of cTnT and hs-cTnT at time of presentation to the emergency department were available from 1159 patients. Patients were grouped according to cutoffs representing the 99th percentile of a healthy reference population or the lower limit of detection if the 99th percentile was below this limit. The cutoffs were 0.010 g/L for cTnT and 0.014 g/L for hs-cTnT. The baseline characteristics of patients segmented according to the cutoffs of the 2 cardiac troponin assays are shown in Table 1 . Patients with cardiac troponin results above cutoff by either of the 2 assays were significantly older; had more cardiovascular risk factors, more often a history of atherosclerotic diseases or events, and a higher TIMI risk score; and more frequently received aspirin, ␤-blockers, and other medical treatments. Patients with only hs-cTnT above cutoff (vs those with both assays above cutoff) more often had a history of known coronary heart disease and related interventions and more frequently were already on aspirin, ␤-blockers, ACE inhibitors, and statins. They also were less likely to be male and had less frequent ST-segment changes and lower TIMI risk scores. The adjudicated diagnosis of the index event was AMI in 184 patients (16%), unstable angina in 164 patients (14%), and noncoronary or chest pain of unknown origin in the remaining 811 patients (Table 1) . These diagnoses were based on local cardiac troponin results, but would not have changed if the analyzed cTnT assay had been applied. Only 1 patient diagnosed with unstable angina showed a cTnT above cutoff for AMI, but this was only a minor increase without a rising and falling pattern. During follow-up (median 16.3 months, interquartile range 12.1-24.0 months), 76 deaths, 42 AMIs, and 65 cardiovascular deaths/AMIs were recorded.
DISCRIMINATORY POWER OF TROPONIN ASSAYS FOR OUTCOME
The prognostic accuracy of hs-cTnT for death, as quantified by the area under the ROC curve, was significantly higher (0.79, 95% CI 0.74 -0.84) than that of cTnT (0.69, 95% CI 0.62-0.76; P Ͻ 0.001) (Fig. 1) . Table 2 lists the prognostic performance of both tests for mortality.
cTnT was not a discriminator for AMI during follow-up (AUC 0.54; 95% CI 0.45-0.63) (Fig. 1 ). hscTnT had better but still limited discriminatory power, with an AUC of 0.62 (95% CI 0.54 -0.70; P for comparison to cTnT ϭ 0.02). These markers had negative predictive values for AMI during follow-up of 96% and 98% but positive predictive values of only 5% and 6%, respectively ( Table 2) .
For the combined endpoint of cardiovascular death or AMI, cTnT gave an AUC of 0.60 (95% CI 0.53-0.68). hs-cTnT had better but still limited discriminatory power, with an AUC of 0.70 (95% CI 0.64 -0.77; P for comparison to cTnT Ͻ0.001) ( Fig. 1 and Table 2 ).
The optimal ROC-derived cutoff for index diagnosis of AMI in our cohort was 0.017 g/L for hs-cTnT.
KAPLAN-MEIER ANALYSES
From Kaplan-Meier analysis for mortality, patients with a cardiac troponin result above cutoff for both assays had the highest mortality during follow-up (21.2%) (Fig. 2) . cTnT Ͻ0.010 g/L but hs-cTnT Ͼ0.014 g/L was associated with a 4-fold increased mortality compared with that of patients with results for both assays below cutoff (12.9% vs 3.2%; log-rank P Ͻ 0.001). From Kaplan-Meier analysis for AMI after the index event, patients with only hs-cTnT above the cutoff had an 8% incidence of AMI, compared with 5.8% in patients with both assays above the cutoff and 3.0% in patients with both assays below cutoff (logrank P ϭ 0.008). The difference in AMI rates in patients with only hs-cTnT above the cutoff compared to those with both assays above the cutoff resulted from only a limited number of events, however, and the KaplanMeier comparison between these subgroups showed no significant difference (log-rank P ϭ 0.61). KaplanMeier analysis for the combined endpoint of cardiovascular death and AMI showed findings similar to those of the analysis for AMI alone, with a similar increased incidence of the combined endpoint in both subgroups with hs-cTnT above cutoff (log-rank P Ͻ 0.001). The second analysis, which examined the endpoint of AMI including the index event, showed an incidence of 70.8% for both assays above cutoff, 18.5% for only hs-cTnT above cutoff, and 4.9% for both assays below cutoff (log-rank P Ͻ 0.001).
COX REGRESSION ANALYSES INCLUDING TIMI RISK SCORE
The TIMI risk score, which includes cTnT Ͼ0.010 g/L as 1 of its components, showed a strong association with mortality and the incidence of AMI and the combined endpoint of cardiovascular death or AMI during follow-up (Fig. 3) . The majority of patients with an adverse event were identified by hs-cTnT Ͼ0.014 g/L, in particular if they had a higher TIMI risk score. The lack of an increase in incidence of subsequent AMI with TIMI risk scores Ͼ4 might be explained by the limited number of patients in these high-risk categories. The HR of the TIMI risk score for mortality was 2.28 (95% CI 1.93-2.69; P Ͻ 0.001), for AMI 1.49 (95% CI 1.22-1.83; P Ͻ 0.001), and for the combined endpoint of cardiovascular death or AMI 1.80 (95% CI 1.52-2.14; P Ͻ 0.001).
hs-cTnT Ͼ0.014 g/L was associated with an HR for mortality of 7.02 (95% CI 4.04 -12.18; P Ͻ 0.001) (Fig. 4A) in univariable Cox regression analysis. After adjustment for the TIMI risk score, hs-cTnT Ͼ0.014 g/L showed an HR of 2.60 (95% CI 1.42-4.74; P Ͻ 0.001) for mortality. Addition of hs-cTnT to the risk analysis, which included cTnT, resulted in a strong improvement of reclassification of patients as demonstrated by an NRI of 0.91 (95% CI 0.67-1.14; P Ͻ 0.001) and the discrimination (IDI ϭ 0.002; P Ͻ 0.001). A significant interaction of hs-cTnT and diagnosis of AMI as index event was found in a Cox regression analysis for mortality (P for interaction ϭ 0.002). No significant interactions with hs-cTnT were seen for age, sex, BMI, or GFR (P for interaction Ͼ0.20). Therefore, we performed subgroup analyses for patients with and without AMI as an index diagnosis (Fig. 4A) . In patients without an index diagnosis of AMI, hs-cTnT did significantly improve the risk prediction of mortality, but not in patients with AMI as index diagnosis.
hs-cTnT Ͼ0.014 g/L had an unadjusted HR of 2.51 (95% CI 1.36 -4.62; P ϭ 0.003) in the Cox regression model for AMI during follow-up (and after the index event). The addition of this marker to the TIMI risk score improved the reclassification, with a NRI of 0.43 (95% CI 0.12-0.74; P ϭ 0.007), but not the discrimination (IDI ϭ 0.009; P ϭ 0.08). hs-cTnT was not independently predictive for AMI after adjustment (HR 1.53; 95% CI 0.76 -3.08; P ϭ 0.23). A similar result was also seen in the subgroup of patients without AMI as the initial event (data not shown). After inclusion of AMIs from the index event in this analysis, hs-cTnT Ͼ0.014 g/L was associated with an adjusted HR of 7.33 (95% CI 4.88 -11.02; P Ͻ 0.001) and a significant improvement of the reclassification (NRI 1.21; 95% CI 1.06 -1.35; P Ͻ 0.001) and discrimination (IDI ϭ 0.029; P Ͻ 0.001).
hs-cTnT Ͼ0.014 g/L had an HR of 3.63 (95% CI 2.17-6.07; P Ͻ 0.001) in the unadjusted Cox regression model for the combined endpoint of cardiovascular death or AMI during follow-up. The addition of hscTnT to the TIMI risk score improved the reclassification, with a NRI of 0.63 (95% CI 0.38 -0.88; P Ͻ 0.001), and the discrimination (IDI ϭ 0.008; P ϭ 0.003). After adjustment, hs-cTnT showed only a nonsignificant trend for prediction of the combined endpoint (HR 1.75; 95% CI 0.98 -3.12; P ϭ 0.06).
To determine the consistency of the results of the Cox regression analyses over time, we repeated the analyses for the first 30 and 365 days of follow-up (Fig.  4B) . For mortality, the HR for the first 30 days was numerically higher. Apart from this analysis, there was almost complete overlap of CIs of the different strata of time for all 3 endpoints, indicating that the effect appeared to be stable over time.
Sensitivity analyses using ROC-derived cutoffs for index diagnosis of AMI (cTnT, 0.010 g/L; hs-cTnT, 0.017 g/L) (Table 2) or cutoffs used for diagnosing 
Discussion
In the evaluation of novel assays for an established cardiac biomarker, it is of pivotal importance to understand how the new assays differ from currently used assays. If the novel assay does not provide incremental or at least similar information, it cannot substitute for the prior assay. When compared with prior-generation assays, high-sensitivity cardiac troponin assays have been shown to have higher accuracy for the early diagnosis of AMI (11, 12, 25 ) . Evidence is needed to deter- Fig. 2 . Kaplan-Meier analyses according to cutoffs of troponin T assays. ϩ, Result above the cutoff; -, result equal to or below the cutoff. cTnT (fourth-generation assay), cutoff of 0.010 g/L (lower limit of detection, since 99th percentile below this cutoff). hs-cTnT, cutoff of 0.014 g/L (99th percentile). P value by log-rank test. mine whether these tests, even while they have demonstrated a good prognostic value (13) (14) (15) (16) (17) (18) , can also improve the risk prediction in patients with acute chest pain compared to currently used assays.
The main finding of our study was the incremental prognostic value of hs-cTnT compared to the current fourth-generation cTnT assay. There were several additional important findings in this analysis. First, hscTnT improved risk prediction even when used in combination with the clinically well-validated TIMI risk score. Second, the incremental benefit for the prediction of death seen with hs-cTnT resulted primarily from the subgroup of patients presenting without AMI. This finding suggests that hs-cTnT might be helpful in the majority of patients with acute chest pain. Patients with AMI benefit from improved early diagnosis by use of hs-cTnT, whereas prediction of mortality is improved in patients without AMI. Third, hs-cTnT outperformed cTnT in the prediction of AMI and the combined endpoint of cardiovascular death or AMI during follow-up and improved the reclassification of patients. Overall, however, the accuracy of hs-cTnT to predict AMI during follow-up was modest. Fourth, patients positive for hs-cTnT but negative for cTnT (the newly identified at-risk patients) had a risk of AMI during follow-up similar to that of patients positive for both markers. These additionally identified patients more often had previously diagnosed coronary heart disease with associated procedures and medications. However, they also had a lower proportion of typical risk factors as shown by the lower proportion of male sex, ST-segment changes, and lower TIMI risk score. Fifth, when analyzing the incidence of AMI including the index event, hs-cTnT above the cutoff in combination with cTnT below the cutoff was already associated with a more than 3-fold increased incidence of AMI compared with patients with both assays below cutoff, which can be explained by its improved sensitivity for AMI.
The substantial increase in the proportion of patients presenting with acute chest pain who have been found to have increased cardiac troponin concentrations associated with the use of novel (commercial availability expected within the US) and highly sensitive assays (10, 26 ) could raise doubt regarding the clinical significance of low-level increases in cardiac troponin and the appropriateness of the 99th percentile cut point. However, results of a subgroup analysis of the Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes (MERLIN)-TIMI 36 trial, which enrolled patients with non-ST segment elevation acute coronary syndromes, showed that even small increases above the 99th percentile detected with a sensitive cardiac troponin assay were associated with a significantly higher risk of death or AMI within 30 days and 12 months (13 ), similar to findings for mortality and heart failure seen in stable patients (17, 18 ) . Our data show similar findings with a high-sensitivity assay and indicate that the prognostic value of hs-cTnT for prediction of clinical outcome did not interact with factors that could potentially affect cardiac troponin concentrations, such as age, sex, or renal function.
A recent subgroup analysis of the Global Use of Strategies to Open Coronary Arteries IV trial (GUSTO IV) trial comparing hs-cTnT with an older cTnT assay demonstrated excellent correlation between these troponin assays, similar to that seen in our analysis (27 ) . hs-cTnT also identified a significant cohort of patients not identified by cTnT that were at a higher risk for death compared with patients with both assays below cutoff. In comparison with our study, however, the transfer of these findings into clinical practice is more difficult, since GUSTO IV evaluated the use of a GP IIb/IIIa inhibitor in patients with acute coronary syn- drome not undergoing an early invasive approach, a practice in conflict with the currently recommended treatment of patients with acute coronary syndrome.
Two important strengths differentiate our study cohort from those presented in previous studies. First, blood samples were drawn immediately upon presentation to the emergency department and not some time thereafter. Second, we recruited consecutive unselected patients and thereby avoided the selection bias introduced by the selection criteria of pharmacologic intervention studies, allowing our results to be easily generalized. Our data suggest that the incremental information provided by hs-cTnT is already present at the earliest point of the clinical evaluation in the emergency department. Whether these additionally identified patients benefit from an early invasive approach as recommended for patients diagnosed with AMI remains to be determined.
Several limitations of our study merit consideration. First, since this is a prospective observational study, we cannot quantify exactly the clinical benefit associated with the increase in prognostic accuracy. Second, we cannot comment on the performance of hs-cTnT among patients with terminal kidney failure requiring dialysis, since such patients were excluded from our study. Third, cardiac troponin concentrations of patients presenting with AMI are confounded per definition by the initial event. Thus, we can neither confirm nor exclude a potential prognostic impact of hs-cTnT in patients presenting with AMI if hs-cTnT were to have been tested several days after the initial event. Our analysis used only troponin concentrations at time of presentation to the emergency department. Thus, we cannot exclude the possibility that troponin concentrations drawn at a later time (e.g., the following day) would have had a better prognostic value. For the index diagnosis, local troponin assays using cutoffs at CV Ͻ10% were used. The MI rate may have been different if local assays used 99th percentile values.
In summary, hs-cTnT improves the prediction of death but not of subsequent AMI in unselected patients presenting to the emergency department with acute chest pain, even when used in combination with a validated clinical risk score including the results of a current-generation cTnT assay. This effect is primarily mediated by a better classification of patients without AMI at the time of testing. Larger studies are needed for 
